Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05406505

Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Effect of Adjuvant Dapagliflozin on Improving the Treatment of Congestion in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Sponsor: Mansoura University

Conditions Acute Heart Failure

Interventions Dapagliflozin 10mg Tab Placebo

Updated 6 times since 2022 Last updated: Aug 1, 2023 Started: Apr 25, 2022 Primary completion: May 1, 2023 Completion: Jul 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Acute Heart Failure, this trial is completed. The trial is conducted by Mansoura University and has accumulated 6 data snapshots since 2022. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Sep 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Apr 2023 — Sep 2023 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Jul 2022 — Apr 2023 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Apr 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mansoura University

Data source: Mansoura University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Al Mansurah, Egypt